Literature DB >> 18023113

Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection.

Long Sun1, Huang-Yang Ye, Ying-Hong Zhang, Yong-Song Guan, Hua Wu.   

Abstract

We report a 55-year-old male who developed advanced hepatic metastasis and peritoneal carcinomatosis after resection of remnant gastric cancer resection 3 mo ago. The patient only received epidermal growth factor (EGF) receptor antibody (Cetuximab) plus recombinant human endostatin (Endostar). Anti-tumor activity was assessed by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computer tomography (PET/CT) at baseline and then every 4 wk. The case illustrates that (18)FDG-PET/CT could make an early prediction of the response to Cetuximab plus Endostar in such clinical situations. (18)FDG-PET/CT is a useful molecular imaging modality to evaluate the biological response advanced hepatic metastasis and peritoneal carcinomatosis to Cetuximab plus Endostar in patients after remnant gastric cancer resection.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18023113      PMCID： PMC4250904          DOI： 10.3748/wjg.v13.45.6115

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  13 in total

1.  Noninvasive imaging of anticancer therapy.

Authors:  Robert J Gillies
Journal:  Mol Cancer Ther       Date:  2003-03       Impact factor: 6.261

2.  Molecular imaging in cancer.

Authors:  Ralph Weissleder
Journal:  Science       Date:  2006-05-26       Impact factor: 47.728

3.  [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.

Authors:  Ryohei Sasaki; Ritsuko Komaki; Homer Macapinlac; Jeremy Erasmus; Pamela Allen; Kenneth Forster; Joe B Putnam; Roy S Herbst; Cesar A Moran; Donald A Podoloff; Jack A Roth; James D Cox
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

4.  Visualization of a primary anti-tumor immune response by positron emission tomography.

Authors:  Chengyi J Shu; Shuling Guo; Young J Kim; Stephanie M Shelly; Amar Nijagal; Pritha Ray; Sanjiv S Gambhir; Caius G Radu; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-17       Impact factor: 11.205

Review 5.  Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.

Authors:  J C Becker; C Muller-Tidow; H Serve; W Domschke; T Pohle
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

6.  VEGF significance in peritoneal recurrence from gastric cancer.

Authors:  Keishiro Aoyagi; Kikuo Kouhuji; Shojiro Yano; Motoshi Miyagi; Takuya Imaizumi; Jinryo Takeda; Kazuo Shirouzu
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

Review 7.  The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

Authors:  Josep Tabernero
Journal:  Mol Cancer Res       Date:  2007-03       Impact factor: 5.852

8.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

9.  Expression of epidermal growth factor receptor in gastric carcinomas.

Authors:  Takuo Takehana; Kazuyoshi Kunitomo; Shioto Suzuki; Koji Kono; Hideki Fujii; Yoshiro Matsumoto; Akishi Ooi
Journal:  Clin Gastroenterol Hepatol       Date:  2003-11       Impact factor: 11.382

10.  Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

Authors:  Fortunato Ciardiello; Roberto Bianco; Roberta Caputo; Rosa Caputo; Vincenzo Damiano; Teresa Troiani; Davide Melisi; Ferdinando De Vita; Sabino De Placido; A Raffaele Bianco; Giampaolo Tortora
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531
View more
  10 in total

1.  CTA combined with CT perfusion for assessing the efficacy of anti-angiogenic therapy in rabbit VX2 tumors.

Authors:  Han Wang; Lin-Feng Zheng; Yan Feng; Xue-Qian Xie; Xiao-Ming Yang; Gui-Xiang Zhang
Journal:  Acad Radiol       Date:  2012-03       Impact factor: 3.173

2.  The inhibition of Endostar on the angiogenesis and growth of gastrointestinal stromal tumor xenograft.

Authors:  Tian-bao Wang; Xiu-qing Wei; Wei-hao Lin; Han-ping Shi; Wen-guang Dong
Journal:  Clin Exp Med       Date:  2011-06-10       Impact factor: 3.984

3.  Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites.

Authors:  Hongmei Wei; Shukui Qin; Xiaojin Yin; Yali Chen; Haiqing Hua; Lin Wang; Ningrong Yang; Yingxia Chen; Xiufeng Liu
Journal:  Oncol Lett       Date:  2015-04-21       Impact factor: 2.967

4.  Clinical value of F-FDG PET/CT in assessing suspicious relapse after rectal cancer resection.

Authors:  Long Sun; Yong-Song Guan; Wei-Min Pan; Zuo-Ming Luo; Ji-Hong Wei; Long Zhao; Hua Wu
Journal:  World J Gastrointest Oncol       Date:  2009-10-15

5.  Hepatic epithelioid hemangioendothelioma after thirteen years' follow-up: A case report and review of literature.

Authors:  Wei-Fang Mo; Yu-Ling Tong
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

6.  Clinical role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative follow up of gastric cancer: initial results.

Authors:  Long Sun; Xin-Hui Su; Yong-Song Guan; Wei-Ming Pan; Zuo-Ming Luo; Ji-Hong Wei; Hua Wu
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

Review 7.  Tumor stroma derived biomarkers in cancer.

Authors:  Malin Sund; Raghu Kalluri
Journal:  Cancer Metastasis Rev       Date:  2009-06       Impact factor: 9.264

8.  Effects of vascular endothelial growth factor and epidermal growth factor on biological properties of gastric cancer cells.

Authors:  Chunfeng Li; Jian Zheng; Yingwei Xue
Journal:  Arch Med Sci       Date:  2019-10-07       Impact factor: 3.318

9.  Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.

Authors:  Zhihua Ren; Yanan Wang; Wenhong Jiang; Wei Dai; Yongping Jiang
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

10.  Deciphering the anti-angiogenic effect of endostatin/cyclophosphamide to normalize tumor micrangium through notch signaling pathway in colon cancer.

Authors:  Jin-Yan Lv; Tai-Yuan Hu; Ruo-Yu Wang; Jin-Ming Zhu; Gang Wang
Journal:  World J Surg Oncol       Date:  2016-01-14       Impact factor: 2.754
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.